(Q36194525)

12 August 2017

1 reference

title

Angiogenesis and hematological malignancies (English)

1 reference

12 August 2017

Soon Thye Lim

1

1 reference

12 August 2017

Alexandra M Levine

series ordinal

2

1 reference

12 August 2017

publication date

1 February 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

10

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

11-24

1 reference

Molecular mechanisms of blood vessel formation

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Hypoxia and the regulation of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Vascular endothelial growth factor B, a novel growth factor for endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Proteolytic processing regulates receptor specificity and activity of VEGF-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

VEGF receptor expression and signaling in human bladder tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Role of soluble mediators in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Regulatory role of vHL/HIF-1alpha in hypoxia-induced VEGF production in hepatic stellate cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Hypoxia-induced angiogenesis during carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Up-regulation of vascular endothelial growth factor in response to glucose deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Antiangiogenic activity of the cleaved conformation of the serpin antithrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Bone marrow angiogenesis and progression in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Interleukin 6 induces the expression of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Thalidomide for previously untreated indolent or smoldering multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Thalidomide for the treatment of patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Cancer immunotherapy: the interferon-alpha experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Successful treatment of an angiogenic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Cellular markers that distinguish the phases of hemangioma during infancy and childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Antiangiogenic chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Weekly paclitaxel infusion as salvage therapy in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Activity of thalidomide in AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400018409

10.1080/10245330400018409

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference